Document:

EX-10.2

 Exhibit 10.2 

Privileged and Confidential 
 FINAL

 LANDOS BIOPHARMA, INC. 

2019 EQUITY INCENTIVE PLAN 
 1.
Purposes of the Plan. The purposes of the Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors, and Consultants and to promote the success of the business of the Company. 

2. Definitions. The following definitions shall apply as used herein and, except as defined otherwise in an Award Agreement, in the Award Agreements.

 “Administrator” means the Board and any Committee or individual appointed to administer the Plan
under Section 4. 
 “Award” means an award described in Section 6. 

“Award Agreement” means the written agreement evidencing the grant of an Award, including any
amendments and attachments thereto. 
 “Award Cycle” means a period of consecutive fiscal years, or
portions thereof, over which Performance Awards are to be earned. 
 “Board” means the Board of
Directors of the Company. 
 “Cause” means, with respect to the termination of employment or service,
the term “Cause” (or similar term) that is expressly defined in either the applicable Award Agreement or a then-effective written agreement between the Grantee and the Company or any Subsidiary or
Parent, or in the absence of such a definition, “Cause” shall be determined in the discretion of the Administrator to mean the Grantee’s: (i) performance of any act or failure to perform any act in bad faith and to the
material detriment of the Company or any Subsidiary or Parent, as determined by the Administrator; (ii) act of dishonesty, intentional misconduct or material breach of any agreement with the Company or any Subsidiary or Parent; or
(iii) commission of a crime involving dishonesty, breach of trust, or physical or emotional harm to any person. 

“Code” means the Internal Revenue Code of 1986, as amended. 

“Committee” means any committee of the Board that is composed of at least two members of the Board.

 “Common Stock” means the common stock, $0.01 par value, of the Company. 

“Company” means Landos Biopharma, Inc., a Delaware corporation, or any successor entity. 

“Consultant” means any person other than an Employee or a Director (solely with respect to rendering
services in such person’s capacity as a Director) who is engaged by the Company or any Subsidiary or Parent to render consulting or advisory services to the Company or such Subsidiary or Parent. 

  
 1 

 “Corporate Transaction” means any of the following:

  

	 	(i)	 a transaction or series of related transactions in which any person (within the meaning of
Section 13(d)(3) or 14(d)(2) of the Exchange Act), other than any person who currently owns more than a majority of the Company’s Common Stock, becomes the beneficial owner (within the meaning of Rule
13d-3 promulgated under the Exchange Act) of more than 50% of the combined voting power of the then outstanding voting securities of the Company, except that any change in the ownership of the stock of the
Company as a result of either an Initial Public Offering or a private financing of the Company that is approved by the Board will not be considered a Corporate Transaction; 

 

	 	(ii)	 a consolidation or merger of the Company with or into another entity, unless the stockholders of the Company
immediately before such consolidation or merger own, directly or indirectly, a majority of the combined voting power of the outstanding voting securities of the corporation or other entity resulting from such consolidation or merger; or

  

	 	(iii)	 the sale of all or substantially all of the assets of the Company. 

Notwithstanding the foregoing, to the extent necessarily to avoid a violation of Section 409A of the Code, a transaction will not be
deemed a Corporate Transaction unless the transaction qualifies as a change in control event within the meaning of Section 409A of the Code, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and
Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time. 
 For the
avoidance of doubt, a transaction will not constitute a Corporate Transaction if: (1) its sole purpose is to change the jurisdiction of the Company’s incorporation, or (2) its sole purpose is to create a holding company that will be
owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction. 

“Director” means a member of the Board or the board of directors of any Subsidiary or Parent. 

“Employee” means an employee of the Company or any Subsidiary or Parent (including a Director who is
also an employee). 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Fair Market Value” means, as of any date, the value of Common Stock determined as follows: 

 

	 	(i)	 if the Common Stock is listed on one or more established stock exchanges or national market systems, its Fair
Market Value shall be the closing sale price for such stock (or the closing bid, if no sales were reported) as quoted on the principal exchange or system on which the Common Stock is listed (as determined by the Administrator) on the date of
determination (or, if no closing sale price or closing bid (as applicable) was reported on that date, on the last trading date that such closing sale price or closing bid was reported), as reported in The Wall Street Journal or such other source as
the Administrator deems reliable; 

  
 2 

	 	(ii)	 if the Common Stock is regularly quoted on an automated quotation system (including the OTC Bulletin Board) or
by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such stock as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, the Fair Market
Value of a share of Common Stock shall be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as
reported in The Wall Street Journal or such other source as the Administrator deems reliable; or 

  

	 	(iii)	 if neither (i) nor (ii) above applies, its Fair Market Value shall be the fair market value determined by
the Board using any measure of value that the Board determines to be appropriate (including, as it considers appropriate, relying on appraisals), and with respect to Options and SARs, in a manner consistent with the valuation principles under
Section 409A of the Code, except as the Board may expressly determine otherwise. 

“Grantee” means an individual who holds an Award. 

“Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the
meaning of Section 422 of the Code. 
 “Initial Public Offering” means the consummation of the
first Public Offering. 
 “Non-Qualified Stock Option” means
an Option not intended to qualify as an Incentive Stock Option. 
 “Option” means an option to
purchase Shares. 
 “Parent” means a “parent corporation” of the Company, whether now or
hereafter existing, as defined in Section 424(e) of the Code. 
 “Performance Awards” means
Awards granted under Section 9. 
 “Performance Goals” means the performance goals established
in connection with the grant of Performance Awards. 
 “Plan” means this 2019 Equity Incentive Plan,
as may be amended or restated from time to time. 
 “Public Offering” means the consummation of a
firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale by the Company of its equity securities. 

  
 3 

 “Restricted Stock” means Shares issued under the
Plan subject to restrictions determined by the Administrator and set forth in the applicable Award Agreement. 

“Restricted Stock Units” means an Award based on the value of Common Stock that is an unfunded and
unsecured promise to deliver Shares, cash, or other property upon the attainment of specified vesting or performance conditions, as determined by the Administrator and set forth in the applicable Award Agreement. 

“SAR” means a stock appreciation right entitling the Grantee to Shares or cash compensation, as
determined by the Administrator and set forth in the applicable Award Agreement, measured by appreciation in the value of Common Stock. 

“Securities Act” means the Securities Act of 1933, as amended. 

“Service Provider” means an Employee, Director, or Consultant. 

“Share” means a share of Common Stock. 

“Subsidiary” means a “subsidiary corporation” of the Company, whether now or hereafter
existing, as defined in Section 424(f) of the Code. 
 “Unrestricted Stock” means Shares issued
under the Plan that are not subject to vesting, forfeiture or similar restrictions pursuant to the applicable Award Agreement. For the sake of clarity, Shares that are only subject to restrictions on transfer, right of first refusal, market stand-off and other similar restrictions shall not, by virtue of such restrictions, be deemed to be Restricted Stock. 

3. Stock Subject to the Plan. 
 (a)
Reserved Shares. Subject to the provisions of Sections 13 and 14 of the Plan, (i) the maximum aggregate number of Shares which may be issued pursuant to all Awards is 2,003,956 Shares, and (ii) the maximum aggregate number of Shares which
may be issued pursuant to Incentive Stock Options is 2,003,956 Shares. The Shares may be authorized but unissued or reacquired Common Stock. 

(b) Automatic Reserved Share Increase. Subject to the provisions of Sections 13 and 14 of the Plan, the maximum aggregate number of Shares
which may be issued pursuant to all Awards and the maximum aggregate number of Shares which may be issued pursuant to Incentive Stock Options each shall be cumulatively increased on January 1, 2020 and each subsequent January 1 in an
amount equal to the least of (i) 5% of the number of Shares issued and outstanding on the December 31 immediately preceding each such January 1, (ii) 1,000,000, or (ii) the number of shares determined by the Administrator. 

(c) Shares Returned to Plan. Any Shares covered by an Award (or portion of an Award) that is forfeited, canceled, reacquired by the Company
prior to vesting, expired (whether voluntarily or involuntarily), satisfied without the issuance of Shares, or withheld upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, or otherwise terminated
(other than by exercise) shall be deemed not to have been issued for purposes of 

  
 4 

 
determining the maximum aggregate number of Shares which may be issued under the Plan. Shares that actually have been issued under the Plan pursuant to an Award shall not be returned to the Plan
and shall not become available for future issuance under the Plan, except that if Shares are forfeited or repurchased by the Company at or less than the original value, such Shares shall become available for future grant under the Plan for all
purposes other than the grant of Incentive Stock Options. 
 4. Administration of the Plan. 

(a) Administration by the Board. Subject to Sections 4(b), 4(c), and 4(g) the Plan will be administered by the Board. 

(b) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the Plan to one
or more Committees. All references in the Plan to the “Administrator” shall mean the Board or a Committee of the Board or the officers referred to in Section 4(c) to the extent that the Board’s powers or authority
under the Plan have been delegated to such Committee or officers. 
 (c) Delegation to Officers. To the extent permitted by applicable law,
the Board or a Committee may delegate to one or more officers of the Company the power to grant Awards, subject to any limitations under the Plan, to Employees, and to exercise such other powers under the Plan as the Board or a Committee may
determine, provided, that the Board or a Committee shall fix certain material terms of the Awards to be granted by such officers (including the exercise price of such Awards, if applicable, which may include a formula or method by which the
exercise price will be determined) and the maximum number of Shares subject to Awards that the officers may grant; provided further, however, that no officer shall be authorized to grant Awards to himself or herself. 

(d) Powers of the Administrator. The Administrator shall have such powers and authority as may be necessary or appropriate for the
Administrator to carry out its functions as described in the Plan, including without limitation the authority (i) to grant Awards and determine recipients and terms thereof, including vesting criteria, any forfeiture events, any vesting
acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, (ii) to determine Fair Market Value, (iii) to determine and measure Performance Goals, (iv) to
amend, modify or terminate any outstanding Award pursuant to Section 11(c), and (v) to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Administrator shall
have full discretionary authority to construe and interpret the terms of the Plan and any Award Agreements entered into under the Plan and to determine all facts necessary to administer the Plan and any Award Agreements. All decisions by the
Administrator shall be made in the Administrator’s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. 

(e) Indemnification. The Administrator shall not be liable for any act, omission, interpretation, construction or determination made in good
faith in connection with the Plan. In addition to such other rights of indemnification as they may have, members of the Board and any Committee (and any individuals to whom authority to act for the Board is delegated in accordance with the Plan)
shall be defended and indemnified by the Company to the extent permitted by law 

  
 5 

 
against all reasonable expenses, including attorneys’ fees, actually and necessarily incurred in connection with the defense of any claim, investigation, action, suit or proceeding, or in
connection with any appeal therein, to which they or any of them may be a party by reason of any action taken or failure to act under or in connection with the Plan, or any Award granted hereunder, and against all amounts paid by them in settlement
thereof (provided such settlement is approved by the Company) or paid by them in satisfaction of a judgment in any such claim, investigation, action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such
claim, investigation, action, suit or proceeding that such person is liable for gross negligence, bad faith or intentional misconduct. Upon the institution of any such action, suit, or proceeding, any such indemnified person against whom a claim is
made shall notify the Company in writing and give the Company the opportunity, within thirty (30) days after such notice and at its own expense, to handle and defend the same before such indemnified person undertakes to handle it on his or her
own behalf. 
 (f) Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the
laws in other countries in which the Company and any Parent or Subsidiary operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which
Subsidiaries, if any, shall be covered by the Plan; (ii) determine which individuals, if any, outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals
outside the United States to comply with applicable foreign laws and regulations; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or
advisable (and such subplans and/or modifications shall be attached to the Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitation contained in Section 3 hereof; and
(v) take any action, before or after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. 

(g) Plan Administration When Shares are Publicly Traded. At any time that any class of equity security of the Company is registered pursuant to
Section 12 of the Exchange Act: (i) the Plan shall be administered so that any Award or transaction will not become subject to (or lose an exemption under) the short-swing profit recovery provisions of Section 16 of the Exchange Act,
and (ii) Awards to Directors who are independent, “non-employee directors” within the meaning of Rule 16b-3 of the Exchange Act shall be made only in
accordance with the terms, conditions, and parameters of a plan, program, or policy for the compensation of such Directors as in effect from time to time. 

5. Eligibility for Awards. Awards other than Incentive Stock Options may be granted to Employees, Directors, and Consultants. Incentive Stock
Options may be granted only to Employees. 
 6. Types and Terms of Awards. 

(a) General. Awards may be made under the Plan in the form of (i) Options, (ii) SARs, (iii) Restricted Stock, (iv) Restricted
Stock Units, (v) Unrestricted Stock, (vi) Performance Awards, and (vii) other stock-based awards or cash incentives that the Administrator determines are consistent with the purpose of the Plan and the interests of the Company. 

  
 6 

 (b) Conditions of Awards. Subject to the terms of the Plan, the Administrator shall
determine the provisions, terms, and conditions of each Award including, but not limited to, the Award vesting schedule, restrictions and restriction periods, repurchase provisions, rights of first refusal, forfeiture provisions, form of payment
(cash, Shares, or other consideration) upon exercise or settlement of the Award, payment contingencies, and satisfaction of any performance criteria. Subject to the terms of the Plan, the Administrator may determine the effect on an Award of the
disability, death, termination or other cessation of employment or service, authorized leave of absence or other change in the employment or service relationship of the Grantee. All of the terms and conditions of an Award shall be as set forth in
the applicable Award Agreement or in the Plan. 
 (c) Discretion of Administrator. Except as otherwise provided by the Plan, each Award may
be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Administrator need not treat Grantees uniformly. In selecting persons to receive Awards under the Plan and in determining the type
and amount of Awards to be granted under the Plan, the Administrator shall consider any and all factors that it deems relevant or appropriate. 

(d) Substitute Awards in Corporate Transactions. Nothing contained in the Plan shall be construed to limit the right of the Administrator to
grant Awards under the Plan in connection with the acquisition by the Company, whether by purchase, merger, consolidation or other corporate transaction, of the business or assets of any corporation or other entity. Without limiting the foregoing,
the Administrator may grant Awards under the Plan to an employee or director of another corporation who becomes eligible to participate in the Plan by reason of any such corporate transaction in substitution for awards previously granted by such
corporation or entity to such person. The terms and conditions of the substitute Awards may vary from the terms and conditions that would otherwise be required by the Plan solely to the extent the Administrator deems necessary for such purpose. Any
Shares subject to these substitute Awards shall not be counted against any of the maximum share limitations set forth in Section 3. 

(e) Fractional Shares. In the case of any fractional share resulting from the grant, vesting, payment or crediting of dividends under an Award,
the Administrator shall have the discretionary authority to (i) disregard such fractional share, (ii) round such fractional share to the nearest lower or higher whole share, or (iii) convert such fractional share into a right to
receive a cash payment. 
 7. Options and SARs. 

(a) General. The Administrator may grant Options and SARs under the Plan and determine the number of Shares to be covered by each Option and/or
SAR, the exercise price and such other terms, conditions and limitations applicable to the exercise of each Option and/or SAR, as it deems necessary or advisable. Subject to Section 7(g), Options granted under the Plan may be either Incentive
Stock Options or Non-Qualified Stock Options. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock
Option. 
 (b) Exercise Price. The exercise price per Share subject to an Option or SAR shall be determined by the Administrator at the time
of grant but shall not be less than 100% of the Fair Market Value on the date of grant. If an Employee owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10% of the combined voting power of

  
 7 

 
all classes of stock of the Company or any Subsidiary or Parent of the Company, and an Incentive Stock Option is granted to such Employee, the exercise price of such Incentive Stock Option shall
not be less than 110% of the Fair Market Value on the grant date. Notwithstanding the foregoing, Options may be granted with a per Share exercise price other than as required above as a substitution for a stock option or stock appreciation right in
accordance with and pursuant to Section 424 of the Code, in the case of an Incentive Stock Option, and pursuant to Section 409A of the Code, in the case of a Non-Qualified Stock Option. 

(c) Term of Options and SARs. The term of each Option and SAR shall be fixed by the Administrator and set forth in the Award Agreement;
provided, however, that no Option or SAR shall be exercisable more than ten (10) years after the date of grant. If an Employee owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more
than 10% of the combined voting power of all classes of stock of the Company or any Subsidiary or Parent of the Company, and an Incentive Stock Option is granted to such Employee, the term of such Option shall be no more than five (5) years
from the date of grant. In accordance with Section 422 of the Code, any Incentive Stock Option exercised later than three (3) months after the Employee ceases to be employed by the Company or any Subsidiary, except in the case of death or
disability (as defined in Section 422 of the Code), will be deemed a Non-Qualified Stock Option. 

(d) Exercisability; Rights of a Stockholder. Options and SARs shall become vested and/or exercisable at such time or times, whether or not in
installments, as shall be determined by the Administrator and set forth in the applicable Award Agreement; provided, however, that the Administrator may at any time accelerate the vesting and/or exercisability of all or any portion of
any Option or SAR. A Grantee shall have the rights of a stockholder only as to Shares acquired upon the exercise of an Option or SAR in accordance with the Plan and applicable Award Agreement (and not as to Shares underlying an unexercised Option or
SAR) and the entry of such Grantee’s name as a stockholder in the books of the Company. 
 (e) Exercise of Options and SARs. Options and
SARs may be exercised in whole or in part by delivery to the Company of a written notice of exercise in such form of notice (including electronic notice) and manner of delivery as is specified by the Administrator, together with payment in full as
specified in Section 7(f) for the number of Shares for which the Option or SAR is exercised. Shares subject to the Option or SAR will be delivered by the Company as soon as practicable following exercise. Neither an Option nor SAR may be
exercised for a fraction of a Share. 
 (f) Payment Upon Exercise. No Shares shall be delivered pursuant to any exercise of an Option or SAR
until payment in full of all required tax withholding, and in the case of an Option, the aggregate exercise price. Payment may be made by one or more of the following methods (or any combination thereof), as determined by the Administrator in its
sole discretion, and subject to any additional requirements in the applicable Award Agreement: 
  

	 	(i)	 In cash, by either certified or bank check, or by wire transfer of immediately available funds;

  

	 	(ii)	 In the form of previously acquired Shares based on the Fair Market Value on the date of exercise;

  
 8 

	 	(iii)	 By surrendering to the Company Shares otherwise receivable on exercise of the Option or SAR; and/or

  

	 	(iv)	 By such other means as is included in the Award Agreement or that the Administrator may accept.

 Options may be exercised pursuant to such cashless exercise procedures as may be approved and implemented by the Administrator from
time to time, including without limitation pursuant to broker-assisted exercise transactions and/or net exercise procedures; provided that, notwithstanding anything to the contrary herein, unless the Administrator gives prior written
approval, a Grantee shall not be entitled to satisfy the requirement of payment in full of any tax withholding, as set forth in the first sentence of this Section 7(f), through any “cashless” or “net exercise” arrangement.
Payment instruments will be received subject to collection. No certificates for Shares so purchased will be issued to the Grantee until the Company has completed all steps it has deemed necessary to satisfy legal requirements relating to the
issuance and sale of the Shares, which steps may include, without limitation, (i) receipt of a representation from the Grantee at the time of exercise of the Option that the Grantee is purchasing the Shares for the Grantee’s own account
and not with a view to any sale or distribution of the Shares or other representations relating to compliance with applicable law governing the issuance of securities, (ii) the legending of the certificate representing the Shares to evidence
the foregoing restrictions, and (iii) obtaining from the Grantee payment or provision for all withholding taxes due as a result of the exercise of the Option, consistent with Section 11(b). The delivery of certificates representing the
Shares to be purchased pursuant to the exercise of an Option will be contingent upon (A) receipt from the Grantee (or a purchaser acting in his or her stead in accordance with the provisions of the Option) by the Company of the full purchase
price for such Shares and the fulfillment of any other requirements contained in the Plan, the Award Agreement or applicable provisions of laws and (B) if required by the Company, the Grantee shall have entered into any stockholders agreements
or other agreements with the Company and/or certain other of the Company’s stockholders relating to the Shares. 
 (g) Annual Limit on
Incentive Stock Options. Each Option shall be designated in the Award Agreement as either an Incentive Stock Option or a Non-Qualified Stock Option. However, notwithstanding such designation, to the extent
that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Grantee during any calendar year (under all plans of the Company and any Subsidiary or Parent) exceeds
$100,000, such Options shall be treated as Non-Qualified Stock Options. For purposes of this Section 7(g), Incentive Stock Options shall be taken into account in the order in which they were granted. The
Fair Market Value of the Shares shall be determined as of the time the Option with respect to such Shares is granted. 
 (h) Early Exercise.
The Award Agreement for an Option may, but need not, include a provision whereby the Grantee may elect at any time while an Employee, Director or Consultant to exercise any part or all of the Option prior to full vesting or the vesting of such
portion. Any unvested Shares received pursuant to such exercise may be subject to a repurchase right in favor of the Company or any Subsidiary or Parent or to any other restriction the Administrator determines to be appropriate. 

  
 9 

 8. Restricted Stock, Restricted Stock Units and Unrestricted Stock. 

(a) General. The Administrator shall determine the terms and conditions of each Award Agreement for Restricted Stock, Restricted Stock Units
and Unrestricted Stock. Award Agreements for Restricted Stock and Restricted Stock Units shall include such restrictions as the Administrator may impose, which restrictions may lapse separately or in combination at such time or times, in such
installments or otherwise, as the Administrator may deem appropriate. 
 (b) Stock Certificates. The Company may require that any
stock certificates issued in respect of Shares of Restricted Stock shall be deposited in escrow by the Grantee, together with a stock power endorsed in blank, with the Company (or its designee). Following the expiration of the applicable restriction
periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Grantee or if the Grantee has died, to the beneficiary designated by the Grantee in the manner determined by the Administrator. In
the absence of an effective designation by a Grantee, the designated beneficiary shall be the Grantee’s estate. 
 (c) Forfeiture and
the Option to Purchase. Except as otherwise determined by the Administrator, upon a Grantee’s termination of employment or service (as determined under criteria established by the Administrator) for any reason during the applicable restriction
period, the Company (or its designee) shall have the right, but shall not be obligated, (i) to repurchase from the Grantee all or part of the Shares of Restricted Stock still subject to restriction at their issue price or other stated or
formula price or (ii) to require forfeiture of such Shares, if issued at no cost. 
 (d) Rights as a Stockholder. Upon (i) the
grant of an Award for Restricted Stock or for Unrestricted Stock or the settlement in Shares of Restricted Stock Units and (ii) payment of any applicable purchase price, the Grantee of such Award shall be entered as a stockholder on the books
of the Company and considered the record owner of such Shares. Without limiting the foregoing, Grantee shall be entitled to (1) vote such Shares if, and to the extent, such Shares are entitled to voting rights and (2) receive all dividends
and any other distributions declared on such Shares; provided, however, that the Company is under no duty to declare any such dividends or to make any such distribution. 

9. Performance Awards. Performance Awards subject to vesting or payment based on the achievement of Performance Goals may be granted under the Plan.
The Administrator shall determine the terms and conditions of the Performance Awards, including the number of Shares covered by the Award, the duration of the Award Cycle, whether the Performance Award will be paid in Shares, cash or a combination,
and any other terms and conditions. In all cases, the Administrator may condition the vesting or value of an Award upon the achievement of Performance Goals; any such Award shall constitute a Performance Award for purpose of this Plan. At the
expiration of the Award Cycle, the Administrator shall evaluate the Performance Award holder’s and/or the Company’s performance in light of any Performance Goals for such Performance Award, and shall determine the number of Shares (or
other applicable payment measures) which have been earned. Each Performance Award shall be subject to an Award Agreement 

  
 10 

 10. Other Awards. 

(a) Other Stock-Based Awards. Subject to the provisions of the Plan, the Administrator may grant other Awards that are valued in whole or in
part by reference to, or are otherwise based upon, Common Stock. Such Awards may be granted either alone or in conjunction with other Awards granted under the Plan. Each such Award shall be confirmed by, and be subject to, the terms of an Award
Agreement. 
 (a) Cash Incentive Awards. Subject to the provisions of the Plan, the Administrator may grant cash incentive awards. 

11. General Provisions Applicable to Awards. 

(a) Transferability of Awards. Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are
granted, either voluntarily or by operation of law, and may be exercised, during the lifetime of the Grantee, only by the Grantee. Notwithstanding the foregoing, the Administrator may provide in an Award Agreement that the Award is transferable by
will, by the laws of descent and distribution, or as permitted by Rule 701 promulgated under the Securities Act. References to a Grantee, to the extent relevant in the context, shall include references to authorized transferees. 

(b) Withholding. The Grantee must satisfy all applicable federal, state, and local or other income and employment tax withholding obligations
before the Company will deliver stock certificates or otherwise recognize ownership of Shares under an Award. The Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not
to or cannot withhold from other compensation, the Grantee must pay the Company the full amount, if any, required for withholding or, if permitted by the Administrator in its discretion, have a broker tender to the Company cash equal to the
withholding obligations. If provided for in an Award or approved by the Administrator in its sole discretion, a Grantee may satisfy such tax obligations in whole or in part by delivery of Shares, including Shares retained from the Award creating the
tax obligation, valued at their Fair Market Value; provided, however, that except as otherwise provided by the Administrator, the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s
minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares surrendered to satisfy tax
withholding requirements must not be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. 
 (c)
Amendment of Awards and Award Agreements. The Administrator may amend, modify or terminate any outstanding Award and Award Agreement, including but not limited to, substituting therefor another Award of the same or a different type, changing
the date of exercise or realization, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Grantee’s consent to such action shall be required unless (A) the Administrator
determines that the action, taking into account any related action, would not materially and adversely affect the Grantee’s rights under the Plan or (B) the change is permitted under Section 13 or 14 hereof. For the avoidance of
doubt, the Grantee’s consent shall not be required if an Option intended to be an Incentive Stock Option is deemed a Non-Qualified Stock Option pursuant to Section 7(a). 

  
 11 

 (d) No Distribution; Compliance with Legal Requirements. The Administrator may require each
person acquiring Shares pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the Shares without a view to distribution thereof. No Shares shall be issued pursuant to an Award until all applicable
securities law and other legal and stock exchange or similar requirements have been satisfied. The Administrator may require the placing of such stop-orders and restrictive legends on certificates for Shares and Awards as it deems appropriate. 

(e) Delivery of Stock Certificates. Stock certificates to Grantees shall be deemed delivered for all purposes when the Company or a
stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the Grantee, at the Grantee’s last known address on file with the Company; provided that stock certificates to be held in escrow
pursuant to Section 8 of the Plan shall be deemed delivered when the Company shall have recorded the issuance in its records. 
 (f)
Uncertificated Shares. To the extent any Shares are uncertificated: (i) such Shares shall be deemed delivered by the Company for all purposes when the Company or a stock transfer agent of the Company shall have given to the Grantee, by
electronic mail or by United States mail, addressed to the Grantee at the Grantee’s last known address on file with the Company, notice of the issuance and recorded the issuance in its records (which may include electronic “book
entry” records); (ii) any reference in this Plan or any Award Agreement to the legending of certificates shall be interpreted to mean the notation in the Company’s records (which may include electronic “book entry” records);
(iii) any provision requiring deposit of stock certificates shall not be deemed breached solely by virtue of the fact that there is no stock certificate representing such Shares; and (iv) the rights of an individual or entity that is entitled
to retain possession of a stock certificate (e.g., as security for performance, as escrowed property, or for similar purposes) shall not be prejudiced solely by virtue of the fact that such Shares are not represented by a stock certificate. 

(g) Trading Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider trading
policy, and such related restrictions, terms and conditions or other policies as may be established by the Administrator from time to time. 
 12.
Conditions Upon Issuance of Shares. 
 (a) General. If at any time the Administrator determines that the delivery of Shares pursuant to
the exercise, vesting or any other provision of an Award Agreement is or may be unlawful under applicable law, the vesting or right to exercise an Award or to otherwise receive Shares pursuant to the terms of an Award Agreement shall be suspended
until the Administrator determines that such delivery is lawful, and shall be further subject to the approval of counsel for the Company with respect to such compliance. The Company shall have no obligation to effect any registration or
qualification of the Shares under federal, state or other laws. 
 (b) Transferability of Shares. Prior to when the applicable Shares are
covered by an effective registration statement under the Securities Act, Shares received pursuant to the exercise, vesting or any other provision of an Award shall not be sold, assigned, transferred, pledged or otherwise encumbered by the Grantee,
except by the laws of descent and distribution or upon approval of the Administrator in its sole discretion. References to a Grantee, to the extent relevant in the context, shall include references to authorized transferees. The transfer
restrictions in this Section 12(b) shall apply in addition to the transfer restrictions, if any, that are generally applicable to Shares under the Company’s bylaws, as may be amended from time to time and in effect at a given time, or
under any notice of exercise or similar agreement under which a Grantee acquires Shares in connection with an Award. 

  
 12 

 (c) Securities Law Compliance. As a condition to the exercise of an Award or the receipt of
Shares pursuant to an Award, the Company may require (i) the person exercising such Award (A) to make such representations and agreements as the Company may consider appropriate to avoid violation of the Securities Act or comparable state
law, and (B) to agree to market standoff obligations in connection with any public offering of Shares of the Company, and (ii) that the certificates evidencing such Shares bear appropriate legends restricting transfer. 

13. Adjustments. In the event of any stock split, reverse stock split, stock dividend, reorganization, recapitalization, combination or exchange
of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Shares other than an ordinary cash dividend, (i) the
number and class of securities available under the Plan, (ii) the number and class of securities and exercise price per Share of each outstanding Option and SAR, (iii) the number of Shares subject to and the repurchase price per Share
subject to each outstanding Restricted Stock Award and Restricted Stock Unit Award, and (iv) the terms of each other outstanding Award shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner
determined by the Administrator; provided, however, that each adjustment to Non-Qualified Stock Options or SARs shall satisfy the requirements of Treas. Reg. §
1.409A-1(b)(5)(v)(D) (or any successor regulation) and each adjustment to Incentive Stock Options shall satisfy the requirements of Treas. Reg. § 1.424-1 (or any
successor regulation); provided, further, that the Administrator will make any adjustment to an Award as is required by Section 25102(o) of the California Corporations Code to the extent that the Company is relying upon the
exemption afforded thereby with respect to the Award. 
 14. Corporate Transaction. The Administrator may provide, in its discretion, with respect to
the treatment of each outstanding Award (either separately for each Award or uniformly for all Awards), upon the date of a Corporate Transaction, for any combination of the following: 

(a) any Option or SAR shall become vested and immediately exercisable, in whole or in part; 

(b) any Restricted Stock or Restricted Stock Unit shall become vested and non-forfeitable, in whole or
in part; 
 (c) any Option or SAR shall be assumed by the successor corporation or cancelled in exchange for substitute stock options in a
manner consistent with the requirements of Treas. Reg. § 1.409A-1(b)(5)(v)(D) (or any successor regulation), in the case of a Non-Qualified Stock Option or SAR, and
Treas. Reg. § 1.424-1(a) (or any successor regulations), in the case of an Incentive Stock Option; 

(d) any Option or SAR that is not exercised as of the date of the Corporate Transaction shall be cancelled for no consideration; 

  
 13 

 (e) any Option or SAR shall be cancelled in exchange for cash and/or other substitute
consideration with a value equal to (A) the number of Shares subject thereto, multiplied by (B) the difference, if any, between the Fair Market Value per Share on the date of the Corporate Transaction or the per share consideration payable
to the Company’s stockholders in the Corporate Transaction (such per share consideration, the “Transaction Consideration”) and the exercise price subject to such Option or SAR; provided, that if the Fair Market Value per
Share on the date of the Corporate Transaction or the Transaction Consideration does not exceed such exercise price, the Administrator may cancel that Option or SAR without any payment of consideration therefor; 

(f) any Restricted Stock or Restricted Stock Unit shall be assumed by the successor corporation or cancelled in exchange for restricted stock
or restricted stock units in respect of the capital stock of any successor corporation; 
 (g) any Restricted Stock shall be redeemed for
cash and/or other substitute consideration with a value equal to (i) the Fair Market Value of an unrestricted Share on the date of the Corporate Transaction or (ii) the Transaction Consideration; 

(h) any Restricted Stock Unit shall, subject to Section 18 hereof, be cancelled in exchange for cash and/or other substitute consideration
with a value equal to (i) the Fair Market Value per Share on the date of the Corporate Transaction or (ii) the Transaction Consideration; and/or 

(i) such other modifications, substitutions, adjustments or amendments to outstanding awards or the Plan as the Administrator deems necessary
or appropriate. 
 In taking any of the actions permitted under this Section 14, the Administrator shall not be obligated to treat all Grantees, all
Awards, all Awards held by a Grantee, or all Awards of the same type identically. Any substitute consideration issued to a Grantee pursuant to this Section 14 may include, to the extent determined by the Administrator, the right to receive
consideration payable in the Corporate Transaction after the closing (e.g., in respect of an earn-out or escrow release). 

15. Effective Date and Term of Plan; Stockholder Approval. 

(a) Adoption of Plan. The Plan shall become effective upon its adoption by the Board. It shall continue in effect for a term of ten
(10) years from the date of adoption unless sooner terminated. 
 (b) Stockholder Approval. No Option or SAR granted under the Plan may
be exercised, no Shares shall be issued under the Plan, and no Restricted Stock Unit shall be settled, until the Plan is approved by stockholders of the Company holding a majority of the outstanding securities of the Company entitled to vote
(determined on an as-converted basis). If such stockholder approval is not obtained within twelve (12) months after the date of the Board’s adoption of the Plan, then all Awards previously granted
under the Plan shall immediately and automatically terminate and cease to be outstanding, and no further Awards shall be granted under the Plan. 

  
 14 

 16. Amendment, Suspension or Termination of the Plan. 

(a) General. Subject to the terms of the Plan, the Board may at any time and from time to time, alter, amend, suspend or terminate the Plan, in
whole or in part; provided that the Board shall obtain stockholder approval of any Plan amendment to the extent necessary to comply with applicable law, rule or regulation. In addition, in no event shall an amendment increase the maximum
number of shares of Common Stock with respect to which Awards may be granted under the Plan without stockholder approval. 
 (b) Limitation
on Grants of Awards. No Award may be granted during any suspension of the Plan or after termination of the Plan. 
 (c) No Effect on
Outstanding Awards. Except as set forth in Section 16(b) no suspension or termination of the Plan shall materially and adversely affect any rights under Awards outstanding at the time of such suspension or termination. 

17. No Employment or Services Rights; Other Compensation and Benefits.  

(a) The Plan shall not confer upon any Grantee any right to employment or service with the Company or any Subsidiary or Parent, nor shall it
interfere in any way with the right of the Company or any Subsidiary or Parent to terminate the Grantee’s employment or service at any time. 

(b) The amount of any compensation deemed to be received by a Grantee pursuant to an Award shall not constitute includable compensation for
purposes of determining the amount of benefits to which the Grantee is entitled under any other compensation or benefit plan or program of the Company or any Subsidiary or Parent, including, without limitation, under any bonus, pension,
profit-sharing, life insurance, salary continuation or severance benefits plan, except to the extent specifically provided by the terms of any such plan. 

18. Section 409A. 
 (a)
It is intended that the provisions of the Plan avoid the adverse consequences under Section 409A of the Code, and all provisions of the Plan and Award agreements shall be construed and interpreted in a manner consistent with that intent. 

(b) No Grantee, or creditors or beneficiaries of a Grantee, shall have the right to subject any deferred compensation (within the meaning of
Section 409A of the Code) payable under the Plan to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment, except as required by applicable law. Except as permitted under Section 409A of
the Code, any deferred compensation (within the meaning of Section 409A of the Code) payable to any Grantee or for the benefit of any Grantee under the Plan may not be reduced by, or offset against, any amount owing by any such Grantee to the
Company or any Subsidiary or Parent. 
 (c) If an Award is subject to Section 409A of the Code and payment is due upon a termination of
employment, payment shall be made upon a separation from service within the meaning of Section 409A of the Code. 
 (d) If, at the time
of a Grantee’s separation from service (within the meaning of Section 409A of the Code), (A) such Grantee is a specified employee (within the meaning of Section 409A of the Code) and (B) an amount payable pursuant to an Award
constitutes nonqualified deferred compensation (within the meaning of Section 409A of the Code) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in
Section 409A of the Code in order to avoid taxes or penalties under Section 409A of the Code, then the Company shall not pay such amount on the otherwise scheduled payment date but shall instead pay it, without interest, on the first day
of the seventh month following such separation from service. 

  
 15 

 (e) Notwithstanding any provision of the Plan to the contrary, the Company reserves the
right to make amendments to any Award as the Company deems necessary or desirable to avoid the imposition of taxes or penalties under Section 409A of the Code. In any case, a Grantee shall be solely responsible and liable for the satisfaction
of all taxes and penalties that may be imposed on a Grantee or for a Grantee’s account in connection with an Award (including any taxes and penalties under Section 409A of the Code), and neither the Company nor any Subsidiary or Parent, or
any other person or entity, shall have any obligation to indemnify or otherwise hold such Grantee harmless from any or all of such taxes or penalties. 

19. Recoupment of Awards. The Administrator may establish such policies and procedures as it deems appropriate to provide for clawback or recoupment of
Awards (or proceeds therefrom). Pursuant to such policies and procedures, among other things, the Administrator may require forfeiture of an Award, repayment of an Award (or proceeds therefrom), or recoupment from other payments otherwise due to a
Grantee or a Grantee’s beneficiary. All Awards under the Plan shall be subject to such compensation clawback or recoupment policy (or policies) that the Company may have in effect from time to time. 

20. Status of Plan. With respect to the portion of any Award that has not been exercised and any payments in cash, Shares or other consideration not
received by a Grantee, a Grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly so determine in connection with any Award. 

21. Construction. Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of
the Plan. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise.

 22. Severability. If any provision of the Plan or any Award is, becomes, or is deemed to be invalid, illegal, or unenforceable in any jurisdiction
or as to any Grantee, such provision shall be construed or deemed amended to conform with applicable law, or if the provision cannot be so construed or deemed amended without, in the sole discretion of the Administrator, materially altering the
intent of the Plan or the Award, such provision shall be severed as to the jurisdiction or Grantee and the remainder of the Plan and any such Award shall remain in full force and effect. 

23. Governing Law. The validity and construction of the Plan and any Award Agreements thereunder shall be governed by the laws of the State of
Delaware, excluding any conflicts or choice of law rules or principles that might otherwise refer construction or interpretation of any provision of the Plan or an Award Agreement to the substantive law of another jurisdiction. 

* * * 

  
 16 

 ADOPTED BY THE BOARD ON ________________, 2019 

APPROVED BY THE STOCKHOLDERS ON __________________, 2019 

  
 17 

 LANDOS BIOPHARMA, INC. 

STOCK OPTION GRANT NOTICE 

(2019 EQUITY INCENTIVE PLAN) 

Landos Biopharma, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (as amended and/or restated as of the
Date of Grant set forth below, the “Plan”), has granted to Grantee an option to purchase the number of shares of the Common Stock set forth below (the “Option”). The Option is subject to all of the
terms and conditions as set forth in this Stock Option Grant Notice (the “Grant Notice”) and in the Plan, the Option Agreement, and the Notice of Exercise, all of which are attached to this Grant Notice and incorporated into
this Grant Notice in their entirety. Capitalized terms not explicitly defined in this Grant Notice but defined in the Plan or the Option Agreement will have the meanings set forth in the Plan or the Option Agreement, as applicable. If the Company
uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank or the information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise
schedule and type of grant) will be deemed to come from the electronic capitalization system and is considered part of this Grant Notice. 
  

			
	Grantee:	  	  

	Date of Grant:	  	  

	Vesting Commencement Date:	  	  

	Number of Shares Subject to Option:	  	  

	Exercise Price (Per Share):1	  	  

	Total Exercise Price:	  	  

	Expiration Date:	  	  

	Exercise Schedule:	  	[Same as Vesting Schedule] [Early Exercise Permitted]
	Type of Grant:2	  	[Incentive Stock Option] [Non-Qualified Stock Option]

  

	Vesting Schedule:	 [Sample Vesting: The Option shall vest as to one-fourth
(1/4th) of the shares subject to the Option on the one-year anniversary of the Vesting Commencement Date, and thereafter shall vest in a series of thirty-six
(36) successive equal monthly installments (in each case rounded down to the nearest whole share, except for the last scheduled vesting installment which may be rounded up), measured from the one-year
anniversary of the Vesting Commencement Date, subject to the Grantee’s Continuous Service (as defined in the Stock Option Agreement) through each such vesting date.] 

 
  

	1 	 The exercise price may be paid by one or a combination of the methods permitted in the Option Agreement.

	2 	 If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Non-Qualified Stock Option. 

  
 18 

 Grantee Acknowledgements: By Grantee’s signature below or by electronic acceptance or
authentication in a form authorized by the Company, Grantee understands and agrees that the Option is governed by this Grant Notice, and the provisions of the Plan and the Option Agreement and the Notice of Exercise, all of which are made a part of
this document. 
 By accepting this Option, Grantee consents to receive this Grant Notice, the Option Agreement, the Plan, and any other Plan-related
documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. Grantee
represents that he or she has read and is familiar with the provisions of the Plan and the Option Agreement. Grantee acknowledges and agrees that this Grant Notice and the Option Agreement may not be modified, amended or revised except in writing
signed by Grantee and a duly authorized officer of the Company. 
 Grantee further acknowledges that in the event of any conflict between the provisions in
this Grant Notice, the Option Agreement, the Notice of Exercise and the terms of the Plan, the terms of the Plan will control. Grantee further acknowledges that the Option Agreement sets forth the entire understanding between Grantee and the Company
regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to Grantee and any written employment
agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and Grantee in each case that specifies the terms that should govern this Option. 

Grantee further acknowledges that this Grant Notice has been prepared on behalf of the Company by Cooley LLP, counsel to the Company and that Cooley LLP does
not represent, and is not acting on behalf of, Grantee in any capacity. Grantee has been provided with an opportunity to consult with Grantee’s own counsel with respect to this Grant Notice. 

This Grant Notice may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the
same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other
transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 
  

									
	Landos Biopharma, Inc.	  		  	Grantee:
					
	By:	  	  
	  		  	By:	  	  

		  	(Signature)	  		  		  	(Signature)
	Title:	  	  
	  		  	Email:	  	  

	Date:	  	  
	  		  	Date:	  	  

 Attachments: Option Agreement, 2019 Equity Incentive Plan and Notice of Exercise 

  
 19 

 LANDOS BIOPHARMA, INC. 

2019 Equity Incentive Plan 

OPTION AGREEMENT 

(INCENTIVE STOCK OPTION OR NON-QUALIFIED STOCK OPTION) 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Landos Biopharma, Inc. (the
“Company”) has granted you an option (the “Option”) under its 2019 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock
indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The Option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict
between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the
Plan. 
 The details of your Option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. Vesting. Your Option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your Continuous Service.

 2. Number of Shares and Exercise Price. The number of shares of Common Stock subject to your Option and your exercise price per
share in your Grant Notice will be adjusted for capitalization adjustments as described in Section 13 of the Plan. 
 3. Exercise
Restriction for Non-Exempt Employees. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a
“Non-Exempt Employee”), and except as otherwise provided in the Plan, you may not exercise your Option until you have completed at least six months of Continuous Service measured from
the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your Option as to any vested portion prior to such six month anniversary
in the case of (i) your death or disability, (ii) a Change in Control in which your Option is not assumed, continued or substituted, or (iii) your termination of Continuous Service on your “retirement” (as defined in the
Company’s benefit plans). 
 4. Exercise prior to Vesting (“Early Exercise”). If permitted in your Grant Notice
(i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your Option, you may elect at any time that is both (i) during the period of your Continuous Service and
(ii) during the term of your Option, to exercise all or part of your Option, including the unvested portion of your Option; provided, however, that: 

(a) a partial exercise of your Option will be deemed to cover first vested shares of Common Stock and then the earliest vesting
installment of unvested shares of Common Stock; 
 (b) any shares of Common Stock so purchased from installments that have not vested
as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

  
 20 

 (c) you will enter into the Company’s form of Early Exercise Stock Purchase
Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred; and 
 (d) if your Option
is an Incentive Stock Option, then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your Option plus all other Incentive Stock Options you hold are exercisable
for the first time by you during any calendar year (under all plans of the Company and Affiliates) exceeds $100,000, your Option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Non-Qualified Stock Options. 
 5. Method of Payment. You must pay the full amount of the exercise
price for the shares you wish to exercise. The permitted methods of payment are as follows: 
 (a) by cash, check, bank draft,
electronic funds transfer or money order payable to the Company; 
 (b) subject to Company and/or Board consent at the time of
exercise and provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the
receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”,
“same day sale”, or “sell to cover”; 
 (c) subject to Company and/or Board consent at the time of exercise and
provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances
or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Company at the time you exercise your Option, will include delivery to the Company of
your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your Option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement
restricting the redemption of the Company’s stock; 
 (d) subject to Company and/or Board consent at the time of exercise, and
provided that the Option is a Non-Qualified Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the
Option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in
respect of the Option exercise; provided, further that you must pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock
will no longer be subject to the Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the “net exercise,” (B) shares are delivered to you as
a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; 

  
 21 

 (e) subject to the consent of the Company and/or Board at the time of exercise,
according to a deferred payment or similar arrangement with you; provided, however, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest
income to the Company and compensation income to the Grantee under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 

(f) in any other form of legal consideration that may be acceptable to the Board. 

6. Whole Shares. You may exercise your Option only for whole shares of Common Stock. 

7. Securities Law Compliance. In no event may you exercise your Option unless the shares of Common Stock issuable upon exercise are
then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act. The exercise of your Option also
must comply with all other applicable laws and regulations governing your Option, and you may not exercise your Option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any
restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 

8. Term. You may not exercise your Option before the Date of Grant or after the expiration of the Option’s term. Except as set
forth in your Grant Notice, the term of your Option expires upon the earliest of the following: 
 (a) immediately upon the
termination of your Continuous Service for Cause; 
 (b) three months after the termination of your Continuous Service for any reason
other than Cause, your Disability or your death (except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three month period your Option is not exercisable solely because of the
condition set forth in the section above relating to “Securities Law Compliance,” your Option will not expire until the earlier of the Expiration Date (as described on the Option’s Grant Notice) or until it has been exercisable for an
aggregate period of three months after the termination of your Continuous Service; provided further, that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within
six months after the Date of Grant, and (iii) you have vested in a portion of your Option at the time of your termination of Continuous Service, your Option will not expire until the earlier of (x) the later of (A) the date that is
seven months after the Date of Grant, and (B) the date that is three months after the termination of your Continuous Service, and (y) the Expiration Date; 

(c) 12 months after the termination of your Continuous Service due to your Disability (except as otherwise provided in
Section 8(d)) below; 
 (d) 18 months after your death if you die either during your Continuous Service or within three
(3) months after your Continuous Service terminates for any reason other than Cause; 

  
 22 

 (e) the Expiration Date indicated in your Grant Notice; or 

(f) the day before the 10th anniversary of the Date of Grant. 

If your Option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option,
the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your Option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or
Disability. The Company has provided for extended exercisability of your Option under certain circumstances for your benefit but cannot guarantee that your Option will necessarily be treated as an Incentive Stock Option if you continue to provide
services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your Option more than three months after the date your employment with the Company or an Affiliate terminates. 

9. Exercise. 
 (a)
You may exercise the vested portion of your Option (and the unvested portion of your Option if your Grant Notice so permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise
price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours. If required by the Company, your exercise may be made contingent on your execution of any additional documents specified by
the Company (including, without limitation, any voting agreement or other agreement between the Company and some or all of its stockholders). 

(b) By exercising your Option you agree that, as a condition to any exercise of your Option, the Company may require you to enter into
an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your Option, (ii) the lapse of any substantial risk of forfeiture to which the shares
of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

(c) If your Option is an Incentive Stock Option, by exercising your Option you agree that you will notify the Company in writing within
15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs within two years after the Date of Grant or within one year after such shares of Common Stock are transferred upon
exercise of your Option. 
 (d) By exercising your Option you agree that you will not sell, dispose of, transfer, make any short sale
of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days
following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules (the
“Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or

  
 23 

 
that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until
the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third
party beneficiaries of this Section 9(d) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. You further agree that the obligations contained in this Section 9(d) will also, if
so determined by the Company’s Board of Directors, apply in the Company’s initial listing of its Common Stock on a national securities exchange by means of a registration statement on Form S-1 under
the Securities Act (or any successor registration form under the Securities Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing
capital stock of the Company for resale (a “Direct Listing”), provided that all holders of at least 5% of the Company’s outstanding Common Stock (after giving effect to the conversion into Common Stock of any outstanding
preferred stock of the Company) are subject to substantially similar obligations with respect to such Direct Listing. 
 10.
Transferability. Except as otherwise provided in this Section 10, your Option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. 

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer
your Option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the Option is held in the trust. You and the trustee must enter into transfer and other
agreements required by the Company. 
 (b) Domestic Relations Orders. Upon receiving written permission from the Board
or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your Option pursuant to the terms of a domestic relations order, official marital
settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are
encouraged to discuss the proposed terms of any division of this Option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic
relations order or marital settlement agreement. If this Option is an Incentive Stock Option, this Option may be deemed to be a Non-Qualified Stock Option as a result of such transfer. 

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this
Option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this Option and receive, on behalf of your
estate, the Common Stock or other consideration resulting from such exercise. 

  
 24 

 11. Transfer Restrictions. You may not Transfer (defined below) any shares of
Common Stock that you acquire upon exercise of your Option without the advance approval and written consent of the Board allowing such Transfer, where such consent may or may not be granted in the Board’s sole and absolute discretion. 

(a) If the Board authorizes a Transfer of the shares, such Transfer will be subject to, and may only occur after satisfying, any right
of first refusal as described in Section 12. The term “Transfer” means any sale, encumbrance, pledge, gift or other form of disposition or transfer of shares of Common Stock or any legal or equitable interest therein.

 (b) In the case of a Transfer, the transferee or other recipient will receive and hold the shares of Common Stock so transferred
subject to the provisions of this Option Agreement, the Plan and the Company’s bylaws and other corporate governance documents to the extent applicable to the Common Stock (and to which the transferee or other recipient may be required to
become a signatory), and there will be no further transfer of such shares except in accordance with the terms of those documents and agreements. 

(c) None of the shares of Common Stock purchased on exercise of your Option will be transferred on the Company’s books nor will the
Company recognize any such Transfer of any such shares or any interest therein unless and until all applicable provisions of this Section 11 have been complied with in all respects. The certificates of stock evidencing shares of Common Stock
purchased on exercise of your Option will bear an appropriate legend referring to the transfer restrictions imposed by this Section 11. 

12. Right of First Refusal. Shares of Common Stock that you acquire upon exercise of your Option are subject to any right of
first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided, however, that if there is no right of first refusal described in the Company’s bylaws at such
time, the right of first refusal described below will apply. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national
securities exchange or quotation system (the “Listing Date”). 
 (a) Prior to the Listing Date, you may not
validly Transfer any shares of Common Stock acquired upon exercise of your Option, or any interest in such shares, unless such Transfer is approved by the Board and made in compliance with the following provisions: 

(i) Before there can be a valid Transfer of any shares of Common Stock or any interest therein, the record holder of the
shares of Common Stock to be transferred (the “Offered Shares”) will give written notice (by registered or certified mail) to the Company. Such notice will specify the identity of the proposed transferee, the cash price
offered for the Offered Shares by the proposed transferee (or, if the proposed Transfer is one in which the holder will not receive cash, such as an involuntary transfer, gift, donation or pledge, the holder will state that no purchase price is
being proposed), and the other terms and conditions of the proposed Transfer. The date such notice is mailed will be hereinafter referred to as the “Notice Date” and the record holder of the Offered Shares will be hereinafter
referred to as the “Offeror.” If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding Common Stock which is subject to the provisions of your
Option, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares of Common Stock acquired upon exercise of your Option will be immediately subject to the
Company’s Right of First Refusal (as defined below) with the same force and effect as the shares subject to the Right of First Refusal immediately before such event. 

  
 25 

 (ii) For a period of 30 calendar days after the Notice Date, or such longer period
as may be required to avoid the classification of your Option as a liability for financial accounting purposes, the Company will have the option to purchase all (but not less than all) of the Offered Shares at the purchase price and on the terms set
forth in Section 12(a)(iii) (the Company’s “Right of First Refusal”). In the event that the proposed Transfer is one involving no payment of a purchase price, the purchase price will be deemed to be the Fair Market
Value of the Offered Shares as determined in good faith by the Board in its discretion. The Company may exercise its Right of First Refusal by mailing (by registered or certified mail) written notice of exercise of its Right of First Refusal to the
Offeror prior to the end of said 30 days (including any extension required to avoid classification of the Option as a liability for financial accounting purposes). 

(iii) The price at which the Company may purchase the Offered Shares pursuant to the exercise of its Right of First Refusal will be the
cash price offered for the Offered Shares by the proposed transferee (as set forth in the notice required under Section 12(a)(i)), or the Fair Market Value as determined by the Board in the event no purchase price is involved. To the extent
consideration other than cash is offered by the proposed transferee, the Company will not be required to pay any additional amounts to the Offeror other than the cash price offered (or the Fair Market Value, if applicable). The Company’s notice
of exercise of its Right of First Refusal will be accompanied by full payment for the Offered Shares and, upon such payment by the Company, the Company will acquire full right, title and interest to all of the Offered Shares. 

(iv) If, and only if, the option given pursuant to Section 12(a)(ii) is not exercised, the Transfer proposed in the notice given
pursuant to Section 12(a)(i) may take place; provided, however, that such Transfer must, in all respects, be exactly as proposed in said notice except that such Transfer may not take place either before the 10th calendar day after the expiration of the 30 day Option exercise period or after the ninetieth 90th calendar day after the expiration of the 30
day Option exercise period, and if such Transfer has not taken place prior to said 90th day, such Transfer may not take place without once again complying with this Section 12(a). The Option
exercise periods in this Section 12(a)(iv) will be adjusted to include any extension required to avoid the classification of your Option as a liability for financial accounting purposes. 

(b) To ensure that the shares subject to the Company’s Right of First Refusal will be available for repurchase by the Company, the
Company may require you to deposit the certificates evidencing the shares that you purchase upon exercise of your Option with an escrow agent designated by the Company under the terms and conditions of an escrow agreement approved by the Company. If
the Company does not require such deposit as a condition of exercise of your Option, the Company reserves the right at any time to require you to so deposit the certificates in escrow. As soon as practicable after the expiration of the
Company’s Right of First Refusal, the agent will deliver to you the shares and any other property no longer subject to such restriction. In the event the shares and any other property held in escrow are subject to the Company’s exercise of
its Right of First Refusal, the notices required to be given to you will be given to the escrow agent, and any payment required to be given to you will be given to the escrow agent. Within 30 days after payment by the Company for the Offered Shares,
the escrow agent will deliver the Offered Shares that the Company has repurchased to the Company and will deliver the payment received from the Company to you. 

  
 26 

 13. Option not a Service Contract. Your Option is not an employment or service
contract, and nothing in your Option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition,
nothing in your Option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.

 14. Withholding Obligations. 

(a) At the time you exercise your Option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your
Option. 
 (b) If this Option is a Non-Qualified Stock Option, then upon your request and
subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your Option a number of whole
shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of
your Option as a liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your Option, share withholding pursuant to the preceding sentence
will not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise
deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your Option. Notwithstanding the filing of such election, shares of Common Stock will be withheld solely from fully vested shares of Common Stock
determined as of the date of exercise of your Option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure will be your sole responsibility. 

(c) You may not exercise your Option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your Option when desired even though your Option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein, if applicable, unless such obligations are satisfied. 

  
 27 

 15. Tax Consequences. You hereby agree that the Company does not have a duty to
design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities
arising from your Option or your other compensation. In particular, you acknowledge that this Option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the “fair
market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the Option. Because the Common Stock is not traded on an established securities market, the Fair
Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by
the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the “fair
market value” as subsequently determined by the Internal Revenue Service. 
 16. Company Policies. Option exercises will be
subject to the Company’s insider trading policy, and other such related restrictions as may be established by the Board from time to time. In addition, this Option will be subject to any compensation clawback or recoupment policies that the
Company may have in effect from time to time. 
 17. Notices. Any notices provided for in your Option or the Plan will be given in
writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the last
address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Option by electronic means or to request your consent to participate in the Plan by
electronic means. By accepting this Option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the
Company or another third party designated by the Company. 
 18. Governing Plan Document. Your Option is subject to all the
provisions of the Plan, the provisions of which are hereby made a part of your Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If
there is any conflict between the provisions of your Option and those of the Plan, the provisions of the Plan will control. 
 19.
Defined Terms. 
 (a) “Affiliate” means, at the time of determination, any “parent” or
“majority-owned subsidiary” of the Company, as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which “parent” or “majority-owned subsidiary” status is
determined within the foregoing definition. 
 (b) “Continuous Service” means that the Grantee’s service
with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Grantee renders service to the Company or an Affiliate as an Employee, Director or Consultant
or a change in the entity for which the Grantee renders such service, provided that there is no interruption or termination of the Grantee’s service with the Company or an Affiliate, will not terminate a Grantee’s Continuous Service;
provided, however, that if the entity for which a Grantee is rendering services ceases to qualify as an Affiliate, as 

  
 28 

 
determined by the Board in its sole discretion, such Grantee’s Continuous Service will be considered to have terminated on the date such entity ceases to qualify as an Affiliate. For
example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the
Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military
leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to
such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Grantee, or as otherwise required by law. 

“Disability” means, with respect to a Grantee, the inability of such Grantee to engage in any substantial gainful activity by reason
of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve (12) months as provided in
Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

  
 29 

 LANDOS BIOPHARMA, INC. 

NOTICE OF EXERCISE 
 This constitutes
notice to Landos Biopharma, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the price set
forth below. Use of certain payment methods is subject to Company and/or Board consent and certain additional requirements set forth in the Option Agreement and the Plan. If the Company uses an electronic capitalization table system (such as Carta
or Shareworks) and the fields below are blank, the blank fields will be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise. 

 

			
	 Option Information
	  	
		
	 Type of Option (check one):
	  	Incentive ☐ Non-Qualified ☐
		  	  

	 Stock Option dated:
	  	
		  	  

	 Number of Shares as to which Option is exercised:
	  	
		  	  

	 Certificates to be issued in name
of:3
	  	
		  	  

		
	Exercise Information	  	
		
	 Date of Exercise:
	  	
		  	  

	 Total exercise price:
	  	
		  	  

	 Cash:4
	  	
		  	  

	 Regulation T Program (cashless
exercise):5
	  	
		  	  

	 Value of _________ Shares delivered with this
notice:6
	  	
		  	  

	 Value of _________ Shares pursuant to net
exercise:7
	  	
		  	  

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the 2019
Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this Option, and (iii) if this exercise relates to an incentive stock
option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this Option that occurs within two years after the date of grant of this Option or within one year after such Shares are
issued upon exercise of this Option. I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic
Transactions Act or other applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

I hereby make the following certifications and representations with respect to the number of Shares listed above, which are being acquired by me for my own
account upon exercise of the Option as set forth above: 
  

	3 	 If left blank, will be issued in the name of the option holder. 

	4 	 Cash may be in the form of cash, check, bank draft, electronic funds transfer or money order payment.

	5 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. 

	6 	 Subject to Company and/or Board consent and must meet the public trading and other requirements set forth in
the Option Agreement. Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an
executed assignment separate from certificate. 

	7 	 Subject to Company and/or Board consent and must be a Non-Qualified
Stock Option. 

  
 30 

 I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the
“Securities Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present intention of
distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. 
 I further acknowledge and
agree that, except for such information as required to be delivered to me by the Company pursuant to the Option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the Option or the
purchase of shares of Common Stock through exercise of the Option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by
law, I hereby waive all inspection rights under Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or
foreign regulation, that are, or may become, applicable to the Company or the Company’s capital stock (the “Inspection Rights”). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in
any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 

I further acknowledge that I will not be able to resell the Shares for at least 90 days after the stock of the Company becomes publicly traded (i.e.,
subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 

I further acknowledge that all certificates representing any of the Shares subject to the provisions of the Option will have endorsed thereon appropriate
legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate of Incorporation, Bylaws and/or applicable securities laws. 

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the
offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect
as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the
underwriters or the Company will request to facilitate compliance with applicable FINRA rules) (the “Lock-Up Period”). I further agree to execute and deliver such other agreements as
may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. I further agree that the obligations contained in this paragraph will also, if so determined
by the Company’s Board of Directors, apply in the Company’s initial listing of its Common Stock on a national securities exchange by means of a registration statement on Form S-1 under the Securities
Act (or any successor registration form under the Securities Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the
Company for resale (a “Direct Listing”), provided that all holders of at least 5% of the Company’s outstanding Common Stock (after giving effect to the conversion into Common Stock of any outstanding preferred stock of
the Company) are subject to substantially similar obligations with respect to such Direct Listing. 
 Very truly yours, 

 

	
	  

	(Signature)
	
	  

	

  
 31 

			
		  	  
 Name (Please
Print)

	Address of Record:	  	  

		  	  

		  	
		  	  

		
	Email:	  	
		  	  

  
 32EX-10.4

 Exhibit 10.4 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement (the
“Agreement”), made effective as of January 1, 2020 (“Effective Date”), by and between Landos Biopharma, Inc. (the “Company”), and Dr. Josep Bassaganya-Riera (“Employee”) provides: 

Employee founded the Company on January 6th of 2017 and has been serving as the Chairman of the Board, President, and Chief Executive Officer
(“CEO”) of the Company since January 6th, 2017, and the parties agree that it is in the best interest of the Employee and the Company to now enter into this Employment Agreement which will supersede any and all other agreements previously
made relating to Employee’s employment other than the Assignment of Inventions, Confidentiality, Non-Competition and Non-Solicitation letter dated September 19th,
2017 (the “Letter”). 
 Employee has certain valuable and unique experience and expertise in matters related to the
Company’s business, and the Company desires to employ Employee under the following terms and conditions. 
 NOW, THEREFORE, in
consideration of the mutual promises and covenants set forth herein, the receipt and sufficiency of which are acknowledged, the Company and Employee agree as follows: 
 1. Job Title and Duties. Employee will continue to be employed as the, President, and Chief Executive Officer (“CEO”) of the Company, reporting to the Board of Directors of the Company (the
“Board”) and also will serve as the Chairman of the Board as described below. During Employee’s employment, Employee shall perform the duties consistent with his job title or as otherwise instructed by the Board. Employee shall devote
substantially all of his business time and attention to the affairs of the Company and shall not engage in any other business without the written consent of the Board, except for the Outside Interests outlined and approved by the Company in
Section 9. The Company and Employee acknowledge that the Employee is currently the Common Stock Director (as such term is defined in the Voting Agreement, dated September 2019, among the Company and certain stockholders of the Company
(“Voting Agreement”)). As required by the Voting Agreement, Employee shall serve as the Chairman of the Board for at least as long as Employee is the Common Stock Director. Additionally, as long as the Employee remains the Chief Executive
Officer of the Company, the Company will use its best efforts to cause Employee to be elected to serve as a member of the Board. Immediately upon termination of Employee’s employment with the Company for any reason, if so requested by the
Board, Employee will resign any and all positions held by him, whether as an officer of the Company or director on the Board or on the board of directors of any subsidiary or affiliate of the Company or as a member of any committees thereof;
provided, that Employee shall not be required to resign his position as a director on the Board pursuant to this Section 1 so long as he serves on the Board as the Common Stock Director, as such term is defined in the Voting Agreement.

 2. Term. This Agreement will commence on the Effective Date and, subject to Section 4, will continue until the
second anniversary of the Effective Date (the “Initial Term”). 

  
 1 

 Following the Initial Term, the employment period will be automatically renewed for successive one-year periods (each, a “Subsequent Term”), unless (i) otherwise terminated as set forth in Section 4 of this Agreement, or (ii) the Company or Employee, as the case may be, sends
the other party a written notice of non-renewal at least 90 days prior to the expiration of the Initial Term or any Subsequent Term, as applicable. The Initial Term of this Agreement, as it may be extended by
any Subsequent Term, is herein referred to as the “Term.” 
 3. Compensation. The Company agrees to provide
Employee, and Employee agrees to accept, as compensation for all services rendered to the Company, the following compensation: 
 (a)
Employee is a salaried, exempt employee. The Company will pay Employee a base salary at an annual rate of Five Hundred Two Thousand and Five Hundred Dollars ($502,500) (“Base Salary”), payable in regular monthly installments or on such
other schedule as the Company may adopt in the future for its employees. The Company will withhold state and federal income taxes, social security taxes and will make other withholdings and deductions required by law or mutually agreed upon in
writing by Employee and the Company. The Company will review Employee’s performance on a yearly basis and, in its discretion, may increase Employee’s Base Salary during the Term of this Agreement. 

(b) Employee shall be eligible for cash bonuses as awarded by the Board to senior management from time to time. For each calendar year, Employee
shall have an annual cash bonus target equal to forty five (45) percent of his then-current Base Salary (“Annual Bonus”). The Annual Bonus is discretionary and will be subject to the Board’s assessment of Employee’s
performance against written personal and Company goals, as well as business conditions at the Company. The Annual Bonus will be subject to Employee remaining employed at the time that the Annual Bonus is paid, which shall occur no later than
March 15 of the calendar year immediately following the calendar year for which the Annual Bonus is being determined. In addition, the Annual Bonus will be subject to the terms of any applicable bonus plan. All bonuses awarded hereunder shall
be subject to state and federal income taxes, social security taxes and other required or customary withholdings and deductions. 
 (c) The
Company will reimburse Employee for reasonable expenses and out-of-pocket costs incurred by Employee in the proper performance of Employee’s duties, subject to
submission of receipts and other documentation reasonably acceptable to the Company and in accordance with other Company policies and procedures with respect to expense reimbursement, as may be adopted and revised from time to time by the Company.

 (d) During Employee’s employment with the Company, he shall be eligible to accrue up to four (4) weeks of vacation and five
days of sick leave per calendar year in accordance with the Company’s vacation and sick leave policies in effect from time to time. Vacation and sick leave shall accrue on a monthly basis on the first day of the month. Upon termination of
employment for any reason, Employee shall be entitled to payment for all accrued, but unused, vacation. Employee shall not be entitled to accrued but unused sick leave upon termination of employment. Employee cannot carry over sick leave from year
to year. 

  
 2 

 (e) During Employee’s employment with the Company, Employee shall be entitled to participate in
all employee benefit plans, practices, and programs maintained by the Company, as in effect from time to time (collectively, “Employee Benefit Plans”), to the extent consistent with applicable law and the terms of the applicable Employee
Benefit Plans. The Company reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole discretion, subject to the terms of such Employee Benefit Plan and applicable law. 

(f) As soon as practicable after the date hereof, Employee will receive a grant of an incentive stock option (to the extent allowable under
Section 422 of the Internal Revenue Code and the remainder shall be a nonqualified stock option) to purchase 300,000 shares of the Company’s common stock at the fair market value of such common stock on the date of grant of the stock
option (“Initial Stock Option”). The Initial Stock Option shall become vested and exercisable over a three-year period, commencing January 1, 2020, with 25% of the Initial Stock Option vesting immediately and 25% vesting twelve months
following January 1, 2020, then the remaining 50% of the Initial Stock Option vesting in equal installments over the twenty-four (24) months thereafter. If, during the Initial Term of this Agreement, an initial public offering of the
Company (the “IPO”) is priced at a “pre-money” valuation of $1,000,000,000 or greater (not including the proceeds of the IPO), Employee will receive a grant, as of the date of pricing of
the IPO, of an option to purchase 150,000 shares of the Company’s common stock at the IPO price or, if greater, the fair market value of the Company’s common stock as determined by the Board (“IPO Option”). The IPO Option shall
become vested and exercisable over a four-year period, commencing on the date of pricing of the IPO, with 25% of the IPO Option vesting twelve months following the date of grant, then the remaining 75% of the IPO Option vesting in equal installments
over the thirty-six (36) months thereafter. If, subsequent to the IPO and prior to September 1, 2022, the market capitalization of the Company (determined by multiplying the daily volume weighted
average stock price of the Company by the number of shares of common stock then outstanding) exceeds $2,000,000,000 over a consecutive 10 calendar day period or over 15 calendar days within a 30 calendar day period, as soon as practicable
thereafter, Employee will receive a grant of an option to purchase 150,000 shares of the Company’s common stock at the fair market value of such common stock on the date of grant of the stock option (the “Performance Stock Option”).
The Performance Stock Option shall become vested and exercisable over a four-year period, commencing on the date of grant, with 25% of the Performance Stock Option vesting twelve months following the date of grant, then the remaining 75% of the
Performance Stock Option vesting in equal installments over the thirty-six (36) months thereafter. Subject to the provisions of 4(c) below, vesting of all of the stock options above is contingent on
Employee remaining in continuous service with the Company through each of the applicable vesting dates. Notwithstanding the foregoing, in the event Employee’s employment is terminated without Cause or Employee resigns for Good Reason and the
termination date occurs within the twelve (12) month period on or immediately following a Change in Control (as defined in the Company’s 2019 Equity Incentive Plan or any successor plan under which a stock option is awarded) in which the
outstanding stock options held by Employee are continued, assumed or substituted for by the Company or the acquiring or surviving entity, then all unvested shares underlying any options granted to Employee during the Term of this Agreement,
including but not limited to the Initial Stock Option, shall become fully vested and exercisable upon such termination. Except as otherwise set forth above, the Initial Stock Option shall be evidenced by the Company’s form of stock option
agreement previously approved by the Board pursuant to the Company’s 2019 Equity Incentive Plan. 

  
 3 

 4. Termination. Subject to other provisions of this Section 4, the Term of this Agreement
shall commence on the Effective Date, and shall continue in accordance with the provisions of Paragraph 2, above, unless terminated in accordance with the following provisions: 
 (a) Termination at the election of the Company for Cause. The Company may, subject to the terms of this Agreement, immediately and unilaterally terminate Employee’s employment hereunder “for
Cause”. In the event of any such termination “for Cause”, Employee shall be entitled solely to (i) accrued and unpaid Base Salary through the date of termination; (ii) accrued but unused vacation and sick leave
through the date of termination in accordance with the Company’s vacation and sick leave policies, as then in effect; (iii) reimbursement for unreimbursed business expenses properly incurred by Employee; and (iv) no severance or other
compensation benefits, other than payments which are required by law (the foregoing items (i), (ii) and (iii) are hereinafter referred to, collectively, as the “Accrued Amounts”). For purposes of this Agreement, Accrued Amounts will
be paid in accordance with the Company’s customary payroll policies and procedures. As used herein, “for Cause” shall include: (i) material misrepresentation made by Employee in the scope of or concerning his employment
with the Company; (ii) insubordination, which is the failure to comply with any valid and legal written directive of the Board; (iii) substantial malfeasance or nonfeasance of duty; (iv) unauthorized disclosure of confidential
information that is likely to cause harm to the Company; (v) Employee’s breach of any material provision of this Agreement, the Letter and any other employment, consulting, advisory, non-disclosure,
invention assignment, non-competition, or similar agreement between Employee and the Company; (vi) Employee’s violation of a material Company policy; (vii) Employee’s conviction of or plea
of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude; or (viii) conduct materially prejudicial or injurious to the business of the
Company. The Board shall have sole discretion to determine the existence of “Cause,” and its determination will be conclusive on Employee and the Company. For purposes of this Agreement, there shall be no termination for Cause
unless a written notice containing a detailed description of the grounds constituting Cause is delivered to the Employee stating the basis for the termination, and the Employee fails to cure, if curable, the violation, neglect or conduct that is the
basis of such claim within thirty (30) days of receiving such notice. If, in the Board’s good faith opinion, cure has not been accomplished by the Employee at the conclusion of such thirty (30) day cure period, the Employee will be
given a reasonable opportunity to be heard by the Board before termination. Notwithstanding the foregoing, the Company shall not be obligated to give advance notice of termination for Cause pursuant to subsection (vii) above, or to
provide Employee with a period to fully cure such violation. 
 (b) Voluntary Termination by Employee. Employee may voluntarily
terminate his employment at any time during the term of this Agreement by providing the Company with ninety (90) days prior written notice of termination (the “Notice Period”). In the event of any such voluntary termination, Employee
shall solely be entitled to the Accrued Amounts. In lieu of providing service pursuant to this Agreement during the Notice Period, the Company may elect, at its sole discretion, for Employee to cease performing or perform at a reduced schedule work
on 

  
 4 

 
behalf of the Company, provided that if the Employee continues to abide by the terms of this Agreement the Company shall pay Employee his full salary during the Notice Period, payable in
accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. 
 (c) At the
Election of the Company for Reasons Other Than Cause. 
 (1) The Company may terminate Employee’s employment hereunder at any
time without Cause by giving ninety (90) days prior written notice to Employee of the Company’s election to terminate. During such period, Employee will be available for the benefit of the Company to assist the Company in matters relating
to a transition or as otherwise directed by the Board. Notwithstanding the foregoing, the Company shall have the option, in its sole discretion, to direct Employee to cease performing or perform at a reduced schedule work on behalf of the Company.
Moreover, in lieu of providing the ninety (90) days prior written notice, the Company may elect to terminate Employee effective immediately; provided, however, in all such cases, that the Company pays Employee his full salary during the ninety
(90) day notice period, payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. 
 (2) If the Company terminates Employee under this Section 4(c), provided that Employee has satisfied the Release Conditions, the unvested shares of the Initial Stock Option that would have become vested during
the twelve (12) months following the termination date shall become fully vested and exercisable upon such termination date. Further, the Company shall also pay to Employee the Accrued Amounts, and if elected by Employee, the Company shall
continue to extend to Employee all group health plan benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Employee as in effect on the termination date until the earlier of (i) the end of the Severance Period (as defined below) or (ii) the date Employee becomes eligible for health benefits through
another employer or otherwise becomes ineligible for COBRA. 
 (3) In the event the Company exercises its right to terminate Employee
under this Section 4(c), provided that Employee executes, delivers to the Company and does not revoke a general release in favor of the Company and its affiliates, parents, subsidiaries, officers, directors, employees and any other releasees as
the Company may determine in a form acceptable to the Company and agreed to by Employee (the “Release”) within the consideration period plus the revocation period provided in the Release (which shall in no event be greater than fifty-two (52) days from Employee’s receipt of the Release) (the “Release Conditions”), the Company shall pay Employee severance as follows: (i) if during the Initial Term, the
Employee’s Base Salary at the then current rate for the remainder of the Initial Term or 12 months, whichever is longer (the “Severance Period”); or (ii) following the Initial Term, the Employee’s Base Salary at the then
current rate for a period of twelve (12) months (“Severance Payments”). The Severance Payments shall be subject to all applicable taxes and other withholdings and deductions as required by law. The Severance Payments shall be paid in
equal monthly installments beginning on the first day of the first month after Employee has satisfied the Release Conditions. 

  
 5 

 (4) In the event the Company exercises its right to terminate Employee under this Section 4(c),
provided Employee has satisfied the Release Conditions, Employee shall also be entitled to payout of the target Annual Bonus, prorated based on the actual number of days worked in the calendar year in which termination occurs    

 (5) Employee’s ability to receive Severance Payments pursuant to Section 4(c) is further conditioned upon him: returning all
Company property per Company policy, but in no event later than ten (10) days after the termination date; complying with any post-termination obligations under this Agreement or any other agreement mutually executed between Employee and the
Company; and complying with the Release including without limitation any non-disparagement and confidentiality provisions contained therein. 

(d) Resignation for Good Reason. 
 (1) Employee may resign from his employment with the Company at any time for “Good Reason”, provided he has not been previously notified by the Company of its intent to terminate his employment for Cause.
In the case of a resignation for Good Reason, Employee shall provide thirty (30) days’ advance written notice to the Board of Employee’s intention to resign for Good Reason, which notice shall specify all of the acts or omissions of
the Company that allegedly constitute Good Reason. Such notice must be provided to the Board within thirty (30) days of discovery of the first act or omission that allegedly constitutes “Good Reason” for Employee’s resignation.
For the avoidance of doubt, Good Reason cannot be established if Employee fails to comply with both of the foregoing 30-day deadlines. During any notice period provided by Employee in connection with his
resignation, the Company may, in its sole discretion, direct Employee not to perform any work or report to the office for part or all of the notice period, although Employee’s compensation and benefits shall continue during such notice period
regardless. For purposes of this Section 4(d), “Good Reason” means the occurrence, without the Employee’s consent, of any one of the following events: (i) a material diminution in Employee’s roles, duties and
responsibilities (other than by reason of a physical or mental incapacity), or a change in Employee’s position within the Company which constitutes a material demotion; (ii) a material reduction (more than 10%) of Employee’s then
existing Base Salary; or (iii) a change in the principal workplace of Employee to a location outside of an 35 mile radius from Blacksburg, Virginia; provided, however, that none of the foregoing events shall constitute Good Reason unless the
Company has failed to remedy or cure the event(s) allegedly constituting Good Reason within the 30-day notice period provided herein. 
 (2) In the event of a resignation for Good Reason, the Company shall pay to Employee the Accrued Amounts, and if elected by Employee, the Company shall continue to extend to Employee all group health plan benefits
to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as “COBRA”), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Employee as in
effect on the termination date until the earlier of (i) the end of the Severance Period or (ii) the date Employee becomes eligible for health benefits through another employer or otherwise become ineligible for COBRA. 

(3) In the event of Resignation for Good Reason, provided Employee has satisfied the Release Conditions, (i) the Company shall pay to Employee
the Severance Payments, in accordance with Section 4(c)(3) of this Agreement and prorated bonus in accordance with Section 4(c)(4) of this Agreement and (ii) Employee’s options shall vest in accordance with Section 4(c)(2)
of this Agreement. 

  
 6 

 (4) Employee’s ability to receive Severance Payments, prorated bonus and accelerated vesting of
options pursuant to this Section 4(d) is further conditioned upon him: returning all Company property; complying with any post-termination obligations under this Agreement or any other agreement between Employee and the Company; and complying
with the Release including without limitation any non-disparagement and confidentiality provisions contained therein. 
 (e) Termination Due to Death or Disability. Employee’s employment with the Company shall automatically terminate upon Employee’s death or Disability (as defined below). In the event that
Employee’s employment is terminated due to Employee’s death or Disability, the Company shall pay to Employee, or his heirs as applicable, solely the Accrued Amounts and any accrued bonus amount to the extent it is earned (as determined by
the Board in good faith). “Disability” shall mean the Employee’s inability, due to physical or mental incapacity, to substantially perform his essential duties and responsibilities with or without a reasonable accommodation under this
Agreement for either (i) 90 consecutive days, or (ii) any 120 days out of any 180-day period, as reasonably determined by the Board. In addition, the Employee or his estate, as the case may be, will have
the right to exercise any vested stock options within thirty (30) days after Employee’s death or Disability. 
 (f) Upon
termination of Employee’s employment for any reason, Employee shall have no right to any compensation, payments, benefits or other remuneration from the Company, except as expressly provided in this Agreement or as required by applicable law.

 5. Construction. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without
regard to its conflict of laws principles. 
 6. Invalidity. It is the desire and intent of the parties that the provisions of this
Agreement be enforced to the fullest extent permissible under the law and public policies applied in each jurisdiction in which enforcement is sought. In the event that any one or more of the provisions of this Agreement is held by a court of
competent jurisdiction to be invalid, prohibited, illegal or unenforceable for any reason, in any respect, that provision or instrument will be ineffective, without invalidating the remaining provisions of this Agreement. 

7. Indemnification. Employee is hereby entitled to indemnification for Employee’s acts or omissions in Employee’s capacity as an
executive or officer of the Company or member of the Company’s Board to the same extent as other senior executives of the Company and in the manner provided by the Company’s bylaws. 

8. Novation and Entire Agreement. This Agreement terminates, replaces and novates any earlier agreement, whether in writing or oral, relating
to this subject matter, except for the Letter, which shall remain in full force and effect. Other than the Letter, this Agreement constitutes the entire agreement among the parties pertaining to the subject matter and supersedes all prior agreements
(including, without limitation, all prior employment agreements or other agreements 

  
 7 

 
regarding employee’s compensation, stock ownership or otherwise), understandings, representations, negotiations and discussions, whether oral or written, of the parties. To the extent there
is any conflict or inconsistency between this Agreement and the Letter, then this Agreement shall control. No supplement, modification or waiver of this Agreement will be binding unless executed in writing by both parties. The parties expressly
waive their right to orally modify the Agreement, including, without limitation, the right to modify the provisions of this Section 8. No waiver of any other provisions of this Agreement will be deemed or will constitute a waiver of any other
provision (whether or not similar), nor will such waiver constitute a continuing waiver unless otherwise provided. 
 9. Outside
Interests. The Company acknowledges that Employee is Chairman of the Board, President and CEO of two other business interests, BioTherapeutics, Inc. (“BTI”) and Nutrition Therapeutics, Inc. d/b/a Pervida (“Pervida”), and is
also a Professor and Director of the NIMML at Virginia Tech (“Virginia Tech”) and Founder of the NIMML Institute (the “Institute”) (BTI, Pervida, Virginia Tech and the Institute collectively mean the “Outside
Interests”). The Company hereby consents to Employee’s continued involvement with the Outside Interests, including Employee’s continued involvement as President and Chairman of the Board of BTI and Pervida, and Founding Member of the
NIMML Institute (a 501(c)(3) organization). The parties agree that Employee will step down in his role of CEO of BTI and Pervida by June 30, 2020. Employee will also resign his roles of Professor and Director with Virginia Tech by no later than
September 30, 2020. The Company specifically represents that Employee’s work for these Outside Interests will not serve as the basis for termination of Employee’s employment with the Company “for Cause” under this Agreement
nor will it constitute a breach of the terms of the Letter or this Employment Agreement. The majority voting power of the Board shall have the right to withdraw its consent in the event the Board reasonably determines that Employee’s continued
involvement with such Outside Interests is interfering with Employee’s responsibilities to the Company. 
 10. Binding Effect.
This Agreement shall inure to the benefit of and be binding upon the parties, their representatives, heirs, permitted assigns and successors in interest. 
 11. Assignment. This Agreement provides for the performance of personal services by Employee and, accordingly, Employee may not assign this Agreement or any of Employee’s interests under this Agreement
or delegate any duty or responsibility incurred by him to another. The Company, at any time and without the consent of Employee, may assign or transfer, for such consideration and on such terms and conditions as it may deem appropriate, this
Agreement to a corporation, partnership or other entity which acquires or otherwise will conduct all or part of the business or operations of the Company; provided, however, that no such assignment or transfer by the Company may in any manner
restrict, limit or modify the interest, duties and responsibilities of Employee or the Company under this Agreement. 
 12. Consent to
Service and Jurisdiction. Any action or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the state of Delaware. The parties hereby irrevocably submit to the exclusive
jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue. Employee expressly submits and consents in advance to such jurisdiction in any action or proceeding commenced
in any such court, waiving personal service of process or other papers issued and agreeing that service of such process or other papers may be made by registered or certified mail to Employee. 

  
 8 

 13. Notices. Any notices, request, demands and other communications provided for by this
Agreement will be sufficient if in writing and delivered in person or sent by certified mail, postage prepaid (in which case notice will be deemed to have been given on the third day after mailing), or by overnight delivery by a reliable overnight
courier service (in which case notice shall be deemed to have been given on the day after delivery to such courier service) to the Employee at the last address the Employee has filed in writing with the Company, with a copy to Eric Blanchard or, in
the case of the Company, at its address specified on the signature page or at such other address as the Company may elect in writing from time to time, attention of its Board . 
 14. Miscellaneous. 
 (a) Representations of Employee. Employee represents and warrants to the
Company that: (i) Employee’s acceptance of employment with the Company on the terms and conditions set forth herein and the performance of his duties hereunder will not conflict with or result in a violation of, a breach of, or a default
under any contract, agreement, or understanding to which he is a party or is otherwise bound; and (ii) Employee’s acceptance of employment with the Company and the full performance of his duties hereunder will not violate any non-solicitation, non-competition, or other similar covenant or agreement of a prior or other employer. 

(b) Mutual Non-Disparagement. Employee agrees and covenants that he will not at any time make,
publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments, or statements concerning the Company, its businesses, or any of its affiliates, parents, subsidiaries, employees, officers, and
existing and prospective customers, suppliers, investors and other associated third parties. The Company agrees that it will instruct its officers and directors not to make, publish, or do or say anything to any person or entity or in any public
forum, directly or indirectly, that reasonably may be expected to have the effect of criticizing Employee, or diminishing or impairing his goodwill and reputation. 
 (c) Cooperation. The parties agree that certain matters in which Employee will be involved during his employment with the Company may necessitate Employee’s cooperation now and/or in the future.
Accordingly, during the course of Employee’s employment with the Company and following the termination of Employee’s employment for any reason, to the extent reasonably requested by the Board, Employee shall cooperate with the Company in
connection with matters arising out of Employee’s service to the Company. Except as specified in Section 4(b) and 4(c)(1), the parties agree that Employee’s cooperation after Employee’s employment with the Company ends shall be
at the Company’s sole expense, including a reasonable hourly rate to compensate Employee for his time and effort. 
 (d)
Survival. Upon the termination of this Agreement or Employee’s employment with the Company, the respective rights and obligations of the parties hereto shall survive such termination to the extent necessary to carry out the intentions of
the parties under this Agreement. 

  
 9 

 (e) Captions. The captions of the Sections of this Agreement are for convenience of
reference only and in no way define, limit or affect the scope or substance of any Section of this Agreement. 
 (f) Execution. This
Agreement may be executed in one or more counterparts, and may be executed on electronically transmitted copies, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. 

(g) Acknowledgement of Full Understanding. EMPLOYEE ACKNOWLEDGES AND AGREES THAT HE HAS FULLY READ, UNDERSTANDS AND VOLUNTARILY ENTERS INTO
THIS AGREEMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT HE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF HIS CHOICE BEFORE SIGNING THIS AGREEMENT. 

15. Taxes; Section 409A 

(a) All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other
deductions required by law. Employee hereby acknowledges that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and Employee will not make any claim against the Company or the Board
related to tax liabilities arising from Employee’s compensation. 
 (b) Anything in this Agreement to the contrary notwithstanding, if
at the time of Employee’s separation from service within the meaning of Section 409A of the Code, the Company determines that Employee is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code,
then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee’s separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one
day after Employee’s separation from service, or (B) Employee’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up
payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their
original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by Employee during the time periods set forth in this
Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement
constitutes “non-qualified 

  
 10 

 
deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Employee’s termination of employment, then such payments or
benefits shall be payable only upon Employee’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section 1.409A 1(h). The Company and Employee intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with
Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to Employee or any
other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. Each installment of any Severance
Payments hereunder is a separate payment for purposes of Section 409A of the Code. 
 [signature page follows] 

  
 11 

 IN WITNESS WHEREOF, Employee and Company have caused this Agreement to be executed by their duly authorized
representatives as of the date first written above. 
  

			
	  
	  	

  

			
	FOR: EMPLOYEE	  	FOR: COMPANY
		
	

	  	

	Signature	  	Signature
		  	Konstantin Poukalov
		
	Josep Bassaganya-Riera	  	 
	Name	  	Name
		
		  	Title: Director
	1013 McBryde Lane	  	1800 Kraft Drive, Suite 216
	 Blacksburg, VA 24060
  
	  	 Blacksburg, VA 24060
  

  
 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]